Local Control of Lung Derived Tumors by Diffusing Alpha-Emitting Atoms Released From Intratumoral Wires Loaded With Radium-224

Cooks, Tomer; Schmidt, Michael; Bittan, H.; Lazarov, Elinor; Arazi, L.; Kelson, I.; Keisari, Yona

doi:10.1016/j.ijrobp.2009.02.063

Cited by 34 publications

(32 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies we have also demonstrated that DaRT inhibited tumor development, extended survival, and reduced lung metastases in mice bearing Squamous cell carcinoma (Arazi et al 2007, Cooks et al 2008, lung carcinoma (Cooks et al 2009a), and pancreatic carcinoma (Horev-Drori et al 2012) derived tumors. DaRT was also eff ective against enzyme converting dUMP to dTMP -which is essential for DNA synthesis and repair.…”

Section: Discussionmentioning

confidence: 77%

Ablation of experimental colon cancer by intratumoral²²⁴Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

Reitkopf-Brodutch

Confino

Schmidt

et al. 2015

International Journal of Radiation Biology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 77%

Ablation of experimental colon cancer by intratumoral²²⁴Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

Reitkopf-Brodutch

Confino

Schmidt

et al. 2015

International Journal of Radiation Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This result suggested that 64 Gy in patients with pT3-4 might be insufficient. The results of a study by Cozzarini et al provided strong support for the use of RT at doses ≥ 70 Gy in pT3-4 patients [38]. Therefore, patients with pT3-4 might need dose escalation for salvage RT after RP.…”

Section: Discussionmentioning

confidence: 99%

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

et al. 2011

View full text Add to dashboard Cite

BackgroundTo evaluate prognostic factors in salvage radiotherapy (RT) for patients with pre-RT prostate-specific antigen (PSA) < 1.0 ng/ml.MethodsBetween January 2000 and December 2009, 102 patients underwent salvage RT for biochemical failure after radical prostatectomy (RP). Re-failure of PSA after salvage RT was defined as a serum PSA value of 0.2 ng/ml or more above the postradiotherapy nadir followed by another higher value, a continued rise in serum PSA despite salvage RT, or initiation of systemic therapy after completion of salvage RT. Biochemical relapse-free survival (bRFS) was estimated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards regression model.ResultsThe median follow-up period was 44 months (range, 11-103 months). Forty-three patients experienced PSA re-failure after salvage RT. The 4-year bRFS was 50.9% (95% confidence interval [95% CI]: 39.4-62.5%). In the log-rank test, pT3-4 (p < 0.001) and preoperative PSA (p = 0.037) were selected as significant factors. In multivariate analysis, only pT3-4 was a prognostic factor (hazard ratio: 3.512 [95% CI: 1.535-8.037], p = 0.001). The 4-year bRFS rates for pT1-2 and pT3-4 were 79.2% (95% CI: 66.0-92.3%) and 31.7% (95% CI: 17.0-46.4%), respectively.ConclusionsIn patients who have received salvage RT after RP with PSA < 1.0 ng/ml, pT stage and preoperative PSA were prognostic factors of bRFS. In particular, pT3-4 had a high risk for biochemical recurrence after salvage RT.

show abstract

“…Their efficacy was attributed to the diffusion of the α-particle-emitting daughters of implanted 224 Ra in the tumor region surrounding the wire (114). An interesting future direction in this particular type of brachytherapy would be stimulation of specific antitumor immunity by the tumor antigens originating from the destroyed tumor (115).…”

Section: Preclinical α-Particle Therapy Delivered By Nanometer-sizmentioning

confidence: 99%

Targeted and Nontargeted α-Particle Therapies

McDevitt

Sgouros

Sofou

2018

Annu. Rev. Biomed. Eng.

View full text Add to dashboard Cite

α-Particle irradiation of cancerous tissue is increasingly recognized as a potent therapeutic option. We briefly review the physics, radiobiology, and dosimetry of α-particle emitters, as well as the distinguishing features that make them unique for radiopharmaceutical therapy. We also review the emerging clinical role of α-particle therapy in managing cancer and recent studies on in vitro and preclinical α-particle therapy delivered by antibodies, other small molecules, and nanometer-sized particles. In addition to their unique radiopharmaceutical characteristics, the increased availability and improved radiochemistry of α-particle radionuclides have contributed to the growing recent interest in α-particle radiotherapy. Targeted therapy strategies have presented novel possibilities for the use of α-particles in the treatment of cancer. Clinical experience has already demonstrated the safe and effective use of α-particle emitters as potent tumor-selective drugs for the treatment of leukemia and metastatic disease.

show abstract

Local Control of Lung Derived Tumors by Diffusing Alpha-Emitting Atoms Released From Intratumoral Wires Loaded With Radium-224

Cited by 34 publications

References 22 publications

Ablation of experimental colon cancer by intratumoral²²⁴Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

Ablation of experimental colon cancer by intratumoral²²⁴Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

Targeted and Nontargeted α-Particle Therapies

Contact Info

Product

Resources

About

Local Control of Lung Derived Tumors by Diffusing Alpha-Emitting Atoms Released From Intratumoral Wires Loaded With Radium-224

Cited by 34 publications

References 22 publications

Ablation of experimental colon cancer by intratumoral224Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

Ablation of experimental colon cancer by intratumoral224Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

Targeted and Nontargeted α-Particle Therapies

Contact Info

Product

Resources

About

Ablation of experimental colon cancer by intratumoral²²⁴Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy

Ablation of experimental colon cancer by intratumoral²²⁴Radium-loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy